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Inhibiting Heat Shock Factor 1 in Human Cancer Cells
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Abstract
Heat shock factor 1 (HSF1) is a master regulator that coordinates chaperone protein expression to enhance cellular survival
in the face of heat stress. In cancer cells, HSF1 drives a transcriptional program distinct from heat shock to promote
metastasis and cell survival. Its strong association with the malignant phenotype implies that HSF1 antagonists may have
general and effective utilities in cancer therapy. For this purpose, we had identified an avid RNA aptamer for HSF1 that is
portable among different model organisms. Extending our previous work in yeast and Drosophila, here we report the
activity of this aptamer in human cancer cell lines. When delivered into cells using a synthetic gene and strong promoter,
this aptamer was able to prevent HSF1 from binding to its DNA regulation elements. At the cellular level, expression of this
aptamer induced apoptosis and abolished the colony-forming capability of cancer cells. At the molecular level, it reduced
chaperones and attenuated the activation of the MAPK signaling pathway. Collectively, these data demonstrate the
advantage of aptamers in drug target validation and support the hypothesis that HSF1 DNA binding activity is a potential
target for controlling oncogenic transformation and neoplastic growth.
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shock proteins (HSPs) to facilitate the folding of damaged proteins
and solubilization of protein aggregates [10]. While this observation suggests an indirect role of HSF1 in cancer progression, a
direct impact of HSF1 on malignancy has been discovered
recently [11]. Indeed, HSF1 is found to be activated in a wide
variety of malignant cells, and the pattern of DNA occupancy by
HSF1 in such cancer cells is different from that of normal cells
exposed to heat shock. Thus, HSF1 drives a distinct transcriptional
program that promotes cellular transformation and maintains
malignant growth. In addition to many classical heat shock genes,
cancer-specific genes in this program support cell-cycle regulation,
signaling, metabolism, adhesion and translation. Because this
HSF1 signature is associated with poor patient outcomes in
different types of human cancers including those of breast, lung
and colon, HSF1 may be a target for general and effective cancer
therapeutics [11].
For the purpose of studying and controlling the function of
HSF1 in cells and organisms, we previously identified an RNA
aptamer, AptHSF-RA1 [12]. The aptamer was initially isolated in
an in vitro selection experiment using Drosophila HSF1 as the
target, and later shown to be able to recognize HSF1 in yeast,
Drosophila and humans. Deletion analysis defined a minimal
binding motif of the aptamer comprised of two stems and one
stem–loop joined by a 3-way junction [12]. This aptamer interacts
with the DNA binding domain and an adjacent linker region of
HSF1, and competes with the heat shock DNA elements (HSEs)

Introduction
The Heat Shock Factor 1 (HSF1) is a transcription factor that
responds to a variety of environmental stressors to activate the heat
shock response in eukaryotes, a protective mechanism conserved
among different kingdoms [1]. Stressful insults, such as thermal
exposure, stimulate HSF1 to act as a master activator of a set of
target genes. In particular, it causes the accumulation of proteins
with chaperoning activities, such as heat shock proteins (HSP),
HSP70 and HSP90, which help maintain intracellular homeostasis
by guarding the proteome against the toxic effects of protein
misfolding and aggregation [2]. While there is only one HSF in
Saccharomyces cerevisiae and Drosophila melanogaster, multiple isoforms
exist in mammals and plants, which appear to have specialized
functions [3–5]. HSF1 function is essential for the stress response
and viability in yeast [6], and important for oogenesis and early
development in Drosophila [7]. HSF1 is also involved in the aging
process in C. elegans [8], as well as in extra-embryonic development
and several important diseases in mammals [9].
Paradoxically, under certain circumstances, HSF1’s ability to
promote cell survival may endanger the overall well-being of a
multicellular organism. A poignant example is the function of
HSF1 in cancer. It has long been noted that cancer cells can
continue to proliferate in hypoxic and hostile microenvironments
that are otherwise growth inhibitory to normal cells. Therefore, it
is not surprising that cancer cells exhibit elevated levels of heat
PLOS ONE | www.plosone.org
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DMEM high glucose medium (ATCC) supplemented with 10%
FBS, 1X Pen/Strep in 5% CO2. Upon growth to confluency, cells
were trypsinized and passed into fresh medium according to
ATCC instructions. These parental cells were transfected with
iaRNAHSF or RevRA1 RNA control-expressing vectors. Nontransfected cells were subsequently eliminated from the population
by culturing the cells in 6 mg/ml blasticidin and washing the cells
24 hrs after transfection. Thereafter, cells were maintained and
grown in (1 ug/ml) blasticidin. Only the blasticidin-resistant cells
were used throughout subsequent assays. For the ‘‘rescue’’
experiments, constructs expressing human HSF1 (hHSF1), human
Hsp90 (hHSP90), human Hsp70 (hHSP70), LacZ, or GFP were
mixed with expression vectors for HSF aptamer (or control RNA)
at a 20:1 ratio to ensure proper and excess expression of the
interested targets relative to the aptamers. After the plasmids were
mixed, each mixture was transfected into HeLa cells in 6-well
dishes. Non-transfected cells were washed away using methods
described above and the remaining cells were maintained in
selection medium.

for binding to HSF1. In yeast cell extracts, the aptamer inhibits
transcription from heat shock promoters, and when expressed in
living yeast cells, it produces a temperature sensitive growth
retardation phenotype and specific decrease of heat shock gene
expression [13]. In Drosophila, this aptamer reduces Hsp83 levels
and causes developmental abnormalities that mimic the phenotypes of Hsp83 reduction. The aptamer also effectively suppresses
the phenotypes induced by constitutively active forms of the EGF
receptor and Raf oncoproteins, which are regulated ‘client’
proteins of Hsp83 [14].
Here in the present study, we report the anti-cancer activity of
this HSF1 aptamer in cultured human cells. We adopted the
dimeric configuration of AptHSF-RA1 used in Drosophila [14],
which was named iaRNA HSF1 (‘‘ia’’ stands for ‘‘inhibitory
aptamer’’), and delivered it into HeLa cervical carcinoma cells in
the form of a synthetic gene by transfection. The anti-cancer
activity of the aptamer was then investigated through three lines of
studies. First, we confirmed the molecular mechanism of the
aptamer action by determining the disruption of HSF1’s
interaction with its cognate DNA elements in vitro and in vivo.
Second, we demonstrated the ability of the aptamer, when
expressed in cancer cells, to promote apoptosis and inhibit colony
formation in soft agar. Finally, we address the issue of specificity in
cells by showing: (1) the aptamer phenotypes are suppressed by
overexpression of HSF1 or HSPs, (2) aptamer expression reduces
HSF1 target gene expression, and (3) aptamer expression reduces
the HSF1 modulated, MAPK signaling pathway. Collectively, our
results agree with previous reports that show that HSF1 is critical
for the maintenance of cellular transformation. Moreover, our
findings raise the interesting possibility that an aptamer that
functionally inactivates HSF1 can be used to block human cancer
progression.

EMSA
The general scheme of electrophoretic mobility shift assay
(EMSA) was adopted and modified from previous work [12]. RNA
probes were internally labeled with [a-32P]UTP by using a T7 in
vitro transcription kit (MAXIscript, Ambion, Austin, TX). The
10 ml binding solution contained 1X binding buffer, 1 mg carrier
yeast RNA, 4 mg carrier BSA, 5 mM DTT, 10% glycerol, 6 units
of SUPERase-In (RNase inhibitor), plus protein and labeled RNA
aptamer. The concentration of the labeled RNA probe is below
1 nM in most experiments. The human HSF1 gene was obtained
from the Thiele Lab [15] and was subcloned into the Gateway
expression system as a His fusion. The bacterially expressed Histagged hHSF protein was purified by Ni-NTA chromatography.
This purified His-tagged hHSF1 protein was incubated with
aptamer RNA at room temperature for 30 min and 10 min at 4u
before loading on a 6–9% native polyacrylamide gel. The gels
contained 1/4 TBE buffer and 1 mM MgCl2 and were run at
100–150 V at 4uC for 1–2 hr.

Methods and Materials
Expression constructs
The sequence of the dimeric aptamer construct, iaRNAHSF1 is
the following (the lowercase letters represent the hammerhead
ribozyme): 59GUCGAGUGACGUUGGCAUCGCGAUACAAAAUUAAGUUGAACGCGAGUUCUUCGGAAUUCAACUGCCUUCGUCAUACUCCUUGAAUUCAACUGCCUUCGGGCAUCGCGAUACAAAAUUAAGUUGAACGCGAGUUCUUGGAGGCUCGACguc uagcgaugugguuucgcuacugaugaguccgugaggacgaaac 39. In the process of constructing the expression vector
for the dimeric aptamer, an antisense control construct, RevRA1,
was generated, using primer sets that swapped the parental and
lagging strands of the aptamer coding region while keeping the
hammerhead unit intact. Both sense and antisense units were
cloned in gateway vectors [14] and moved into pDest51
(Invitogen) for expression of the aptamer and the control in
mammalian cells. The coding sequence of ‘‘rescuing’’ proteins and
their controls, including HSF1, HSP90, HSP70, LacZ and GFP,
was each cloned downstream of the CMV promoter in a different
vector with G418 as the selective marker.

RT-PCR
RT-PCR was performed 24 hours post transfection according
to a protocol described previously using the following primers.
iaRNAHSF1 F:
59-GTCGAGTGACGTTGGCATCG
iaRNAHSF1 R:
59- GACGTCGAGCCTCCAAGAAC
iaRNARev F:
59-GTCGAGCCTCCAAGAACTCG
iaRNARev R:
59- GACGTCGAGTGACGTTGGCA

Chromatin Immunoprecipitation (ChIP)
ChIP assay was performed 36 hours post transfection according
to a protocol described previously [16] using antibodies against
HSF1 or HSF2 kindly provided by Dr. Richard Morimoto.

Cell culture and transfection
Cells used in this study were obtained from the ATCC and
maintained according to the manufacturer instructions. HeLa
(CCL-2), IMR-90 (CCL-196), 293T (CRL-3216), MCF7 (HTB22), U87 MG (HTB-14), and BE(2)-M17 (CRL-2267) cells were
grown in E-MEM low glucose medium (ATCC) supplemented
with 10% FBS, 1X Pen/Strep in 5% CO2. MDA-MB-231 (CRMHTB-26) were grown in RPMI media supplemented with 10%
FBS, 1X Pen/Strep in 5% CO2. The 293T cells were grown in
PLOS ONE | www.plosone.org

Western blots
Samples were prepared 72 hrs post-transfection for molecular
analyses unless otherwise specified. For the examination of
caspase-3 samples were prepared between 72–96 hrs. In brief,
cells were fed every 48 hrs, and samples were collected by
centrifugating the media, pelleting the cells. Also, adherent cells
were scrapped in PBS, pelleted and combined with the cells in the
2
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media. Thereupon, samples were lysed in the presence of nonionic detergents containing protease inhibitors, and the samples
were boiled in the presence of 6X-SDS. Conventional Western
blot protocols were used with the following antibodies. Primary
Antibodies: G6PDH was purchased from Sigma (A9521). All other
antibodies were purchased from Cell Signaling Inc.: HSF1
(No. 4356), Hsp90 (No. 4875), Hsp70 (No. 4872), Hsp60
(No. 4870), Hsp40 (No. 4868), Calnexin (No. 2433), GRP78
(No. 3177), EGFR,p (No. 2234), Erk1/2,p (No. 9146), total
Erk1/2 (No. 9102), Caspase-3 (#9662). The PARP antibody was
anti PARP-DBD, a gift from Dr. W.L. Kraus, and transglulaminase (TGM2) was a gift from Dr. R. Cerione’s laboratory
purchased from Thermo Scientific. Secondary antibodies were
used according to proper immunoreactivity. PVDF membranes
were blocked using 5% BSA and membranes were incubated
primary antibodies overnight at 4uC.

Apoptotic assay
Apoptosis was observed by quantifying the number of HeLa
cells containing fragmented nuclei as visualized by DAPI staining
under the microscope. In these experiments, parental, iaRNAHSF
or RevRA1 RNA control cells were observed for 96 hrs post
transfection. In these experiments, non-transfected iaRNAHSF was
removed by culturing the cells in 6 mg/ml blasticidin and washing
the cells 24 hrs after transfection. Only the blasticidin-resistant
cells were used throughout subsequent assays. All statistical
analyses in this study were calculated using student’s t-test.

Figure 1. Specific binding of the aptamer to human HSF1 in
vitro. (A) Electrophoretic motility shift assay (EMSA) using radiolabeled
iaRNAHSF1 (1 nM) and increasing amounts of human HSF1 protein
shows that the aptamer binds to its target avidly. (B) Quantification of
independent EMSA reveals the apparent affinity of the iaRNAHSF1 for
HSF1 as Kd,25 nM (n = 5).
doi:10.1371/journal.pone.0096330.g001

Anchorage independent growth assay
66103 semi-stable transfected cells were plated on 6-well dishes
in appropriate medium supplemented with 3% agarose (Type VII,
Sigma A4018) over a warm layer of pre-solidified medium
containing 6% agarose (Type VII, Sigma A4018). Five days after
plating the cells a new 1 cm layer of media was plated over the
growing cells. HeLa cells containing 17-AGG had a final
concentration of 8.8 ug/dL 17-AAG agar mixture. The ability
of cells to grow on soft agar was evaluated after 14 days. Colonies
were analyzed under the light microscope.

iaRNAHSF1 and HSF1 occurs with high affinity and is relatively
selective.
Next, we transfected the iaRNAHSF1-expressing vector into a
cancer and a non-transformed cell line. We chose HeLa cervical
carcinoma cells as a representative cancer cell line, because they
are one of the most commonly used and well characterized human
cancer cell lines [18]. As a non-transformed cell line, we used
IMR-90 cells, which are non-transformed, non-immortalized
human lung fibroblasts [19]. As a control for the functional
aptamer, we used the RevRA1 expressing vector. To confirm the
expression of the constructs in the cells, we performed reverse
transcription and quantitative PCR (RT-qPCR) assays using
primer sets that recognize the dimeric iaRNAHSF1 or the control
RevRA1 24 hours post-transfection. Our results showed that the
RNA aptamer levels were similar for both the aptamer and the
control RNA in HeLa and IMR-90 cells (Figure 2A).
To confirm the molecular mechanism of aptamer action, we
determined whether iaRNAHSF1 effectively prevented HSF1 from
binding to its regulatory DNA elements in cells. For this purpose,
we performed chromatin immunoprecipitation (ChIP) assays on
iaRNAHSF1 or RevRA1 expressing HeLa cells (36 hrs posttransfection, prior to the cells undergoing apoptosis—see below)
using an antibody specific to mammalian HSF1 [20]. We found
that the iaRNAHSF1 expression significantly compromised HSF1
binding to key heat shock promoters (Hsp90 and Hsp70) in vivo
(Figure 2B). Because mammals contain two heat shock proteins,
HSF1 and HSF2, and the DNA binding domain is highly
conserved between them, we also tested whether our aptamer
inhibits HSF2 binding. We found that iaRNAHSF1 expression
similarly prevents HSF2 binding to the Hsp90 and Hsp70 promoter
in vivo (Figure 2B). It is possible that the aptamer inhibits both

Results
iaRNAHSF1 prevents HSF1 from binding to its regulatory
DNA elements in HeLa carcinoma cells
Previously, we developed a method for delivering RNA
aptamers into the nuclei of cells as synthetic genes [17] and used
it to express the aptamer for HSF1, AptHSF-RA1, in Drosophila
[14]. This RNA construct, named iaRNAHSF1, contains two
aptameric units for enhanced avidity and a hammerhead ribozyme
in which the 59 and 39 ends of the RNA are protected to facilitate
folding and stability. We adapted this construct by placing its
coding sequence under the control of the EF-1a promoter in a
mammalian expression vector. We also made a control construct,
named RevRA1, in which the aptamer moiety of the iaRNAHSF1
was replaced by its antisense sequence. Before using it on cells, we
produced this RNA by in vitro transcription and determined its
avidity for purified human HSF1 in an electrophoretic mobility
shift assay (EMSA) (Figure 1A) using purified human HSF1
protein (Figure S1A). Here, the iaRNAHSF1 generated a shifted
complex with an apparent Kd of 25 nM (Figure 1B). In contrast,
the RevRA1 control did not show any binding. In addition, when
limiting amounts of iaRNAHSF1 was incubated with high amounts
of purified BSA (1 mM), no shifted band was observed. Together,
these in vitro results demonstrated that the interaction between
PLOS ONE | www.plosone.org
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Figure 2. Expression of the RNA construct targeting HSF1 inhibits its occupancy at heat shock loci in vivo. (A) Control RNA (RevRA1) and
aptamer RNA (iaRNAHSF1) constructs are expressed to similar levels in HeLa and IMR90 cells after 24 hrs post transfection (RNA values normalized to
GAPDH, n = 3). (B) Disruption of HSF1’s interaction with its cognate DNA elements by iaRNA HSF1. ChIP assays in iaRNAHSF1 (or RevRA1) expressing
HeLa cells show that iaRNAHSF1 expression can effectively inhibit HSF1 binding to the Hsp90 and Hsp70 promoter loci in vivo (n = 3). Antibodies used
in ChIP assays are specific for mammalian HSF1 or HSF2 proteins [20]. BG = Background.
doi:10.1371/journal.pone.0096330.g002

to form colonies in anchorage-independent (soft agar) growth
assays, an in vitro measurement of tumorgenicity. As expected,
HeLa cells expressing a control RNA sequence (RevRA1) formed
large colonies in soft agar (Figure 4); however, HeLa cells
expressing iaRNAHSF1 did not. This indicated that the HeLa
cells expressing the HSF1 aptamer that did not undergo apoptosis
within the first 96 hours of its expression are compromised in their
transformation capacity. These findings provide further support
that HSF1 is indeed required for maintenance of the transformed
cancer phenotype, similar to previous reports [22].
Because HSP90 is co-regulated by HSF1 and is important for
cancer cell growth [23], we further compared the inhibitory effects
of iaRNAHSF1 against a potent Hsp90 inhibitor 17-(Allylamino)17-demethoxygeldanamycin (17-AAG) on colony formation in soft
agar. Similarly to iaRNA expressing cells, HeLa cells grown in the
presence of 150 nM 17-AAG were unable to form colonies in soft
agar (Figure 4). Overall, these findings suggest that the functional
inactivation of HSF1 by iaRNAHSF1 reduces expression of key
HSF1-regulated genes that in turn are critical for maintenance of
the transformed phenotype.

transcription factors or the inhibition of one factor binding might
affect the promoter occupancy of the other, as both HSF1 and
HSF2 are known to regulate specific heat shock genes [21].
Nonetheless, the much lower levels of HSF2 at the promoters,
relative to HSF1 (note the 50-fold difference in y-axis scale),
detected by ChIP at the Hsp90 and Hsp70 promoters and the
reduced affinity of the aptamer for HSF2 (Figure S1B) suggest that
the primary inhibitory effects of the aptamer on downstream gene
expression is through HSF1, at least under these conditions in
HeLa cells.

iaRNAHSF1 expression induces apoptosis and attenuates
the transforming capabilities of cancer cells
Next, we investigated the effect that the aptamer has on the
survival of HeLa cells and the non-transformed IMR-90 cells.
Four days (96 hrs) after transfecting the cells with either
iaRNAHSF1 or RevRA1, cellular viability and apoptosis was
quantified by direct observation of those cells that were actively
undergoing cell blebbing, nuclear breakdown and chromatic
fragmentation. We found that aptamer expression in the nontransformed IMR-90 cells caused little, if any morphological
changes (Figure 3A) or induction of cell death (Figure 3B). In
contrast, the aptamer caused an approximately 9-fold increase in
cell death of the HeLa cancer cell line (63% of the population,
p = 0.0001). As already demonstrated above in Figure 2A, these
differences were not due to differences in the levels of aptamer
expression between the non-transformed and transformed cancer
cell lines. To demonstrate the generality of this effect, we then
asked whether expression of the iaRNAHSF1 in the chemically
transformed human 293T kidney cell line would similarly kill the
cells. We found that iaRNAHSF1 expression in the 293T cells
dramatically causes the cells to round up and detach from their
culture plates, similar to HeLa cells (Figure 3A). Compared to the
parental and control cells there was an approximately 7-fold
increase of apoptosis in the iaRNAHSF1 expressing 293T cells, with
a p-value of 0.0018 (Figure 3B).
Since a fraction of the iaRNAHSF1-expressing cancer cells did
not undergo apoptosis (approximately 30%), we sought to
determine whether these cells were compromised in their ability
PLOS ONE | www.plosone.org

iaRNAHSF reduced chaperone levels and attenuated the
MAPK pathway in HeLa cells
Drug target validation and therapeutic development requires
rigorous assurance of specificity. This issue is pertinent to the
HSF1 aptamer described here, as it was isolated using an
orthologous protein. However, lack of off-target effects is difficult
to prove in the complex milieu of living cells. Thus, we
approached this issue from three different angles at the molecular
level to demonstrate the causality between aptamer expression and
the loss of the transformed phenotype in human cancer cells. First,
we took a genetic approach that is similar to factor titration or
add-back experiments where the aptamer induced effects are
reversed by the addition of excess target protein [17]. Recently, we
successfully used this strategy in Drosophila and found that the
developmental abnormalities induced by the iaRNAHSF1 could be
suppressed by the over-expression of HSF1 [14]. Following this
example, we examined whether HSF1 over-expression could
rescue cancer cells that express iaRNAHSF1 from undergoing
4
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Figure 3. HSF1 inhibition attenuates cancer cell survival. (A) iaRNAHSF1 expression does not affect normal cells (IMR90), yet induces an
abnormal morphology in HeLa cervical carcinoma and chemically transformed kidney cells (293T). (B). Nuclear condensation and fragmentation
assays reveal that iaRNAHSF1 expression induces ,10-fold increase in apoptosis in HeLa cells (p,0.0001) (n = 8), and ,7-fold increase in apoptosis in
293T cells (p,0.0001) (n.8). Furthermore, iaRNAHSF1 induced apoptosis in effectively suppressed by the over-expression of molecular chaperones
(HSF1 p,0.006, Hsp90 p,0.005, or Hsp70 p,0.002), but not random proteins (GFP or LacZ) (n.8).
doi:10.1371/journal.pone.0096330.g003

apoptosis. We found that ectopic expression of HSF1 or HSF1regulated genes that are important for promoting cell survival,
namely, Hsp70 and Hsp90, can rescue the aptamer-mediated
apoptotic response, compared to the expression of control proteins
(LacZ or GFP) (Figure 3B).
Second, we confirmed the causality between aptamer expression
and its effect on HSF1 inhibition by measuring the level of the

PLOS ONE | www.plosone.org

products of genes known to be controlled by HSF1 binding, as the
inhibition of HSF1 binding by the aptamer should cause a
decrease in these proteins. We measured the total levels of various
molecular chaperone proteins 72 hrs post transfection in parental
(non-transfected), control RNA (Rev) and iaRNAHSF1-expressing
HeLa cells (Figure 5A). Importantly, the levels of HSP70,
Calnexin, transglutaminase 2 (TGM2), and Grp78 were severely
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Figure 4. iaRNAHSF1 expression attenuates transformed
growth. HSF1 inhibition by iaRNAHSF1 inhibits transformed growth in
soft agar. Soft agar analysis of non-transfected HeLa cells (top left) or
control RNA over-expressing HeLa (bottom left), shows that iaRNAHSF1
over-expression (bottom right) inhibits cellular transformation (colony
formation) in a similar manner as treatment of HeLa cells with 150 nM
17-AAG (top right) (Day 14).
doi:10.1371/journal.pone.0096330.g004

decreased in aptamer expressing cells. HSP90 expression was also
reproducibly decreased, though to a lesser extent than HSP70. In
contrast, the level of the mitochondrial specific HSP60 chaperone
was not affected by the aptamer, suggesting that HSP60 is either a
highly stable protein with a long half-life that is tolerant of the
proteolytic events of apoptosis or its expression is independent of
HSF1 transcriptional activity. In these experiments, apoptosis was
detected by assaying for the cleavage of the caspase-3 target
PARP. To address whether the observed decrease in HSP70,
Calnexin, transglutaminase (TGM2), and Grp78 was due to HSF1
inhibition or a consequence of the of the aptamer inducing
apoptosis, we measured the total levels of chaperones in HeLa cells
that expressed iaRNAHSF but were prevented from entering
apoptosis by co-expressing HSP90. Similar to what we observed in
cells expressing only the iaRNAHSF1, the cells expressing both
iaRNAHSF1 and HSP90, we observed a general decrease in the
total levels of select molecular chaperones, HSP70 (,50%),
Calnexin (,50%), and Grp78 (,25%) compared to parental
HeLa or control cells (expressing RevRA1) (Figure 5B, n = 4). This
observation suggests that the reduction of molecular chaperones
by iaRNAHSF1 is due, at least partially, to the general decrease of
HSF1 activity on its gene targets.
We validate the above results and exploit the power of
mammalian genetics by probing for HSP70 and HSP90 using
mouse embryonic fibroblast that have been derived from viable
and fertile HSF1 null mice (hsf12/2) generated in Benjamin
Ivor’s laboratory [24]. Among mammals, HSF1 displays high
structural and functional conservation [15,20] In a similar manner
as HSF1 inhibition by the aptamer, we find that hsf12/2 cells
have relatively minor effects on the total levels of Hsp90 protein,
yet displays major effects on Hsp70 under normal growth
conditions when compared with wild-type MEFs (Figure S2).
Third, we examine how inhibiting HSF1 by our aptamer
attenuates the activation of the MAPK signaling pathway. The
Drosophila MAPK pathway was previously reported by us to be
affected by the HSF1 aptamer [14]. Likewise, the Lindquist and
Gius Laboratories have demonstrated that HSF1 depletion also
affect this pathway [22–23,25]. Here we show in human cells that
PLOS ONE | www.plosone.org

Figure 5. Effective targeting of HSF1 activity reduces the levels
of molecular chaperone proteins. (A) Western blot analysis
showing the depletion of specific molecular chaperone proteins in
aptamer or control expressing cells. Hsp90 co-expression rescues
specific molecular chaperones observed in HSF1 inhibited aptamer
expressing cells. The asterisk indicates PARP degradation product, a
marker of apoptosis. The left most three lanes are a serial dilution of
parental line extracts that provides a quantification standard curve. (B)
Quantification of the results observed in panel A (n = 4, error indicates
%SEM).
doi:10.1371/journal.pone.0096330.g005

HSF1 inhibition by the aptamer affected the overall levels of
clinically relevant oncoproteins, Ras, Raf, and Akt, prior to the
onset (48 hrs) and during aptamer induced apoptosis (96 hrs). In
comparison to the RevRA1 control, the aptamer expressing cells
showed a progressive decrease in the levels of Ras, Raf, and Akt in
a manner that was also consistent with the decreasing levels of fulllength caspase-3, a bonified marker of apoptosis [26] (Figure S3A).
We find that these results can be partially suppressed by coexpression of hHSF1 both in biochemical and morphological
assays (Figure S3 A&B).
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To directly investigate the ability of iaRNAHSF1 to inhibit
MAPK activity in human cancer cells, we stimulated HeLa cells
expressing the aptamer or the control RNA with the mitogen,
epidermal growth factor (EGF), and examine the effects it had on
the activation of the EGF receptor or MAPK signaling by
collecting cells 10 minutes after treatment and assaying the
samples by Western blotting. Importantly, these experiments were
performed in a time when the cells were not actively undergoing
apoptosis as visualized by the intact PARP protein (36 hrs post
transfection) (Figure 6A). Overall, we find that parental or control
RNA-expressing HeLa cells express a considerable amount of
epidermal growth factor receptor (EGFR) that can be activated in
response to epidermal growth factor stimulation (p-EGFR)
(Figure 6A). In contrast, targeting HSF1 activity with the aptamer
decreased the amount of activated EGFR (p-EGFR) (Figure 6A).
To investigate the effect of this aptamer had on mitogenic
signaling activity, we probed for activated Erk1/2 levels, members
of the MAPK that function downstream of the EGFR. Here, we
find that cells expressing the HSF1 aptamer contain reduced
amounts of actived Erk1/2 (phosphorylated) that is accompanied
by an ,75% reduction in the total levels of Erk1/2 protein,
compared to the cells expressing the control aptamer (Figure 6B).
In a similar fashion and as a proof of principle, we complement
these experiments using WT and hsf12/2 MEFs and find that
HSF1 K.O. cells display a compromised ability to active Erk1/2
(p-Erk1/2) (Figure S4). This attenuated MAPK signaling response
can be suppressed by over-expressing k-RasG12V in hsf12/2 MEF
cells.
To further assess how HSF1 modulates MAPK signaling, we
measured the levels of activated EGFR (phosphorylated) or Erk1/
2 protein (total and phosphorylated) in aptamer-expressing cells
that either over-expressed HSP90 or its co-chaperone HSP70
(36 hr post transfection). Here, over-expression of either HSP90 or
HSP70 is sufficient to rescue the loss of either EGFR activation or
Erk1/2 expression, resulting in an apparently normal mitogen
response (Figure 6 A&B). We hypothesize that over-expression of
these molecular chaperones results in the formation of a
chaperone complex that enhances the stabilities of various
oncoproteins that promote cancer cell survival. In this regard,
we compare the effect of Hsp70 or Hsp90 inhibition in HeLa and
other clinically relevant human cancer cells including brain
glioblastoma (U87 MG), neuroblastoma (SK-N-BE(2)-M17), triple
negative (ER-, PR-, Her2-) breast adenocarcinoma (MSA-231),
and estrogen responsive (ER+, PR+, Her22) breast adenocarcinoma (MCF7) (Figure S5). Interestingly, we find that HeLa cells
and brain glioblastomas are particularly sensitive to Hsp90
inhibition, while neuroblastomas and both forms of breast
adenocarcinomas are sensitive to Hsp70 inhibition. Collectively,
our results suggest that HSF1 regulates specific molecular
chaperones that promote oncogenic signaling and the survival of
human tumors.

Figure 6. HSF1 aptamer inhibits mitogenic signaling. (A) HSF1
inhibition attenuates EGF receptor activation following the addition of
EGF to HeLa cells. (B) HSF1 inhibition by iaRNAHSF1 causes a depletion
of the total levels and activated forms of Erk1/2. The left most three
lanes are a serial dilution of parental line extracts that provides a
quantification standard curve. Ectopic expression of HSP70 or HSP90
suppresses the inhibition of mitogenic signaling in the iaRNAHSF1
expressing cells.
doi:10.1371/journal.pone.0096330.g006

DNA is not an easy task, and there is no current molecule or drug
in commercial or clinical use that can disrupt this interaction.
The difficulty of finding small molecules to interrupt DNAprotein interaction stems from the nature of the interface. DNA
binding transcription factors generally bind to an extended stretch
of base pairs covering a relatively large surface area, a biophysical
feature that small molecule inhibitors have a hard time competing
against. In this regard, RNA aptamers have a unique advantage,
as RNA molecules share quite a few common structural features
with DNA. For example, several RNA aptamers have been
isolated to target the DNA-binding domain of the pro-inflammatory protein NFkB [27,28]. Structural analysis of one such NFkB
aptamer revealed that the RNA was mimicking the cognate DNA
element [29]. This aptamer not only inhibited the transcriptional
activities of NFkB at the molecular level, but also demonstrated a
potent anti-cancer activity in a mouse model [30]. In our own
previous work, we isolated aptamers for the yeast TATA binding
protein that are able to interrupt DNA binding and inhibit
transcription [31,32]. Similarly, the aptamer against HSF1
described here, AptHSF-RA1, binds to the DNA binding domain
and adjacent linker region, effectively competing with HSE for
HSF1 binding [12,14]. These examples collectively demonstrate
the capabilities of macromolecular agents in the perturbation of
DNA-protein interaction.
One major challenge of macromolecular drugs is delivery.
Nevertheless, before aptamers can be used in pre-clinical or
clinical studies, their utility can be exploited as useful agents in
drug target validation studies as demonstrated here. Currently,
many drug target validation methods commonly use gene knockout or RNAi technologies to gain insights of the underlying

Discussion
HSF1 supports highly malignant human cancers, including the
most aggressive forms of breast, lung, and colon cancer [11]. It
rewires the transcriptome in cancer cells, and activates the
expression of not only classical heat shock proteins, but also many
other genes involved in multiple processes critical for the
malignant behavior of cancer. Because this HSF1-driven transcriptional program is strongly associated with metastasis and
death in a wide range of cancers, HSF1 could become an effective
target for cancer therapeutics [11]. However, disrupting high
affinity protein-DNA interaction such as the HSF1 binding to
PLOS ONE | www.plosone.org
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molecular mechanisms of disease. Unfortunately, not every protein
is amenable to such inhibition, nor do these strategies provide
sufficient information about the particular domains of the specific
drug target in question. In recent years, we have generated a
comprehensive set of data regarding the activity of the HSF1
aptamer described herein using three organisms from different
biological kingdoms [12–14]. Because HSF1 is so highly conserved
in nature, each model system has been distinctly suited and
allowed us to study specific aspects of biology according to the
unique experimental tractability realized by the molecular tools
provided by each system. In at least two systems, we exploit the
RNA aptamer technology to further understand the role of HSF1
and its regulation of molecular chaperones during development,
stress, growth and survival [14].
Relevant to the case of HSF1, only a small class of naturally
occurring molecules have been identified that inhibits molecular
chaperones, and of these, only a handful have been tested to
sensitize cancer cells to pharmacological treatment [25]. Among
these, the naturally occurring anthamycin compounds like
geldanamycin are better understood and have been found to
inhibit Hsp90’s function by binding to the ATPase domain. In
recent years, geldanamycin derivatives have shown clinical benefit
as seen in the phase I treatment of refractory metastatic or solid
tumors [33] and the multicenter phase II trials in relapsed or
refractory multiple myeloma [34]. Unfortunately, it has not
yielded much benefit in the phase II advanced treatment of
ovarian and peritoneal cancers [35] or the multicenter phase II
trial treatment of castration-resistant prostate cancer [36]. In these
refractory cases, these particular tumors might rely more heavily
on other members of the HSF1 regulated chaperone network for
survival. For this reason, future studies might benefit by focusing
on the identification of new classes of inhibitors against the HSF1
regulated chaperone network in order to help improve the overall
clinical outcomes for patients with cancer.

steady state levels in hsf12/2 MEFs. The left most three lanes are
a serial dilution of parental WT extracts that provides a visual
standard (n = 4).
(TIF)
Figure S3 Suppression of iaRNAHSF1 effects by human

HSF1 over-expression. (A) Western blot analysis of HeLa cells
demonstrates the time dependent and progressive loss of clinically
significant oncoproteins (Ras, Raf, and Akt) by iaRNAHSF1
expression. Apoptosis can be visualized by the degradation of
full-length caspase-3 starting at 48–96 hrs post transfection (lane 5
&6). (Lanes 1–3 = serial dilutions of non-transfected parental
HeLa cells at 96 hrs, lane 4 = whole cell extract of HeLa overexpressing the RNA control at 96 hrs; lane 5 & 6 = whole cell
extract of HeLa cells over-expressing iaRNAHSF1 48 & 96 hrs
respectively; lane 7 = whole cell extract of HeLa cells overexpressing iaRNAHSF1 & human HSF1 protein at 96 hrs). (B)
Differential interference contrast imaging of HeLa cells show that
human HSF1 or human Hsp90 over-expression can effectively
suppress many of the morphological defects induced by
iaRNAHSF1 expression (96 hrs) (compare this figure with samples
from figure 3).
(TIF)
Figure S4 MAPK signaling is attenuated in hsf12/2
MEF’s. In comparison of treatment of WT MEFs (lanes 1–3) with
the potent mitogen, EGF, hsf12/2 cells display decreased levels of
Erk1/2 activation (p-Erk1/2) (lane 4). This abnormal signaling
response can be effectively suppressed by direct over-expression of
constitutively activated K-RasG12V (compare lanes 4–6).
(TIF)
Figure S5 Differential sensitivity of human cancer cells
to Hsp70 or Hsp90 inhibition. (A) Differential interference
contrast imaging of HeLa, human brain glioblastoma (U87 MG),
neuroblastoma (SK-N-BE(2)-M17), and triple negative (ER-, PR-,
Her2-) breast adenocarcinoma (MSA-231), following Hsp70
inhibition (0.32 g/dL myricetin) or Hsp90 inhibition (8.8 ug/dL
17-AAG) (all samples taken at 72 hrs post drug treatment). (B)
Quantification of nuclear condensation and DNA fragmentation
(apoptotic assays) of panel (A) and estrogen responsive (ER+, PR+,
Her2-) breast adenocarcinoma (MCF7) (n = 4).
(TIF)

Supporting Information
iaRNAHSF1 binds avidly to human HSF1 and
HSF2. A) Bacterially expressed and His tagged full-length human
HSF1 and HSF2 protein used in the in vitro binding assays used in
this study. In vitro binding assays included proteins from the
following bacterial preparations: HSF1a2, HSF2a6. B). Electrophoretic motility shift assay (EMSA) using radiolabeled iaRNAHSF1 (1 nM) and increasing amounts of human HSF2 protein
shows that the aptamer binds to this target with an apparent
affinity of 100–200 nM (values quantified by %shifted total
complex).
(TIF)
Figure S1
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contrast, the observed Hsp90 levels are only is moderately affected
by HSF1 deletion, partially because this gene is under the
transcriptional activity of both HSF1 & HSF2 [21]. The Hsp90
client protein, tissue transglutaminase (TGM2) displays decreased
Figure S2

Author Contributions
Conceived and designed the experiments: HHS JTL. Performed the
experiments: HHS MAA. Analyzed the data: HHS MAA RAC HS JTL.
Contributed reagents/materials/analysis tools: HHS MAA RAC HS JTL.
Wrote the paper: HHS MAA RAC HS JTL.

References
3. Sarge KD, Zimarino V, Holm K, Wu C, Morimoto RI (1991) Cloning and
characterization of two mouse heat shock factors with distinct inducible and
constitutive DNA-binding ability. Genes Dev 5(10): 1902–11.
4. Schuetz TJ, Gallo GJ, Sheldon L, Tempst P, Kingston RE (1991) Isolation of a
cDNA for HSF2: evidence for two heat shock factor genes in humans. Proc Natl
Acad Sci 88(16): 6911–5.

1. Wu C (1995) Heat shock transcription factors: structure and regulation. Annu
Rev Cell Dev Biol 11: 441–69.
2. Morimoto RI (1998) Regulation of the heat shock transcriptional response: cross
talk between a family of heat shock factors, molecular chaperones, and negative
regulators. Genes Dev 12(24): 3788–96.

PLOS ONE | www.plosone.org

8

May 2014 | Volume 9 | Issue 5 | e96330

Anti-Cancer Activity of an RNA Aptamer for HSF1

5. Czarnecka-Verner E, Yuan CX, Scharf KD, Englich G, Gurley WB (2000)
Plants contain a novel multi-member class of heat shock factors without
transcriptional activator potential. Plant Molecular Biology 43(4): 459–71.
6. Wiederrecht G, Seto D, Parker CS (1998) Isolation of the gene encoding the S.
cerevisiae heat shock transcription factor. Cell 54(6): 841–53.
7. Jedlicka P, Mortin MA, Wu C (1997) Multiple functions of Drosophila heat
shock transcription factor in vivo. Embo J 16(9): 2452–62.
8. Morley JF, Morimoto RI (2004) Regulation of longevity in Caenorhabditis
elegans by heat shock factor and molecular chaperones. Mol Biol Cell 15(2):
657–64.
9. Xiao XZ, Zuo XX, Davis AA, McMillan DR, Curry BB, et al. (1999) HSF1 is
required for extra-embryonic development, postnatal growth and protection
during inflammatory responses in mice. EMBO J 18(21): 5943–52.
10. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J (2006) Targeting
Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel 9(4): 483–95.
11. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, et al. (2012) HSF1 drives
a transcriptional program distinct from heat shock to support highly malignant
human cancers. Cell 150(3): 549–62.
12. Zhao X, Shi H, Sevilimedu A, Liachko N, Nelson HCM, et al. (2006) An RNA
aptamer that interferes with the DNA binding of the HSF transcription
activator. Nucleic Acids Res 34(13): 3755–61.
13. Wang S, Zhao X, Suran R, Vogt VM, Lis JT, et al. (2010) Knocking down gene
function with an RNA aptamer expressed as part of an intron. Nucleic acids
research 38(15): e154.
14. Salamanca HH, Fuda N, Shi H, Lis JT (2011) An RNA aptamer perturbs heat
shock transcription factor activity in Drosophila melanogaster. Nucleic acids
research. 39(15): 6729–40.
15. Liu KD, Liu LP, Santoro N, Thiele DJ (1997) Conservation of a stress response:
human heat shock factors functionally substitute for yeast HSF. EMBO J 16(21)
6466–77.
16. Boehm AK, Saunders A, Werner J, Lis JT (2003) Transcription factor and
polymerase recruitment, modification, and movement on dhsp70 in vivo in the
minutes following heat shock. Mol Cell Biol 23(21): 7628–37.
17. Shi H, Hoffman BE, Lis JT (1999) RNA aptamers as effective protein
antagonists in a multicellular organism. Proc Natl Acad Sci 96(18): 10033–8.
18. Landry JJ, Pyl PT, Rausch T, Zichner T, Tekkedil MM, et al. (2013) The
Genomic and Transcriptomic Landscape of a HeLa Cell Line. G3 3(8): 1213–
24.
19. Nichols WW, Murphy DG, Cristofalo VJ, Toji LH, Greene AE, et al. (1977)
Characterization of a new human diploid cell strain, IMR-90. Science
196(4285): 60–3.
20. Sarge KS, Murphy SP, Morimoto RI (1993) Activation of heat shock gene
transcription by heat shock factor 1 involves oligomerization, acquisition of
DNA-binding activity, and nuclear localization and can occur in the absence of
stress. Mol Cell Biol. 13(3): 1392–1407.
21. Ostling P, BjorkJK, Roos-Mattjus P, Mezger V, Sistonen L (2007) Heat shock
factor 2 (HSF2) contributes to inducible expression of hsp genes through
interplay with HSF1. The Journal of Biological Chemistry 282(10): 7077–86.

PLOS ONE | www.plosone.org

22. Dai C, Whitesell L, Rogers AB, Lindquist S (2007) Heat shock factor 1 is a
powerful multifaceted modifier of carcinogenesis. Cell 130(6): 1005–18.
23. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, et al. (2003)
Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in
vitro and in vivo radiation response of cervical tumor cells via the heat shock
protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63(24):
8984–95.
24. Yan LJ, Christians ES, Liu L, Xiao XZ, Sohal RS, et al. (2002) Mouse heat
shock transcription factor 1 deficiency alters cardiac redox homeostatsis and
increases mitochondrial oxidative damage. EMBO J 21(10): 5164–72.
25. Sawai A, Chandariapaty S, Greulich H, Gonen M, Ye Q, et al. (2008) Inhibition
of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR)
expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68(2):
589–96.
26. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicologic
Pathology,35(4): 495–516.
27. Lebruska LL, Maher LJ 3rd (1999) Selection and characterization of an RNA
decoy for transcription factor NF-kappa B. Biochemistry 38(10): 3168–74.
28. Wurster SE, Maher LJ 3rd (2008) Selection and characterization of anti-NFkappaB p65 RNA aptamers. RNA 14(6): 1037–47.
29. Huang DB, Vu D, Cassiday LA, Zimmerman JM, Maher LJ 3rd, et al. (2003)
Crystal structure of NF-kappaB (p50)2 complexed to a high-affinity RNA
aptamer. Proc Natl Acad Sci 100(16): 9268–73.
30. Mi J, Zhang X, Rabbani ZN, Liu Y, Su Z, et al. (2006) H1 RNA polymerase III
promoter-driven expression of an RN aptamer leads to high-level inhibition of
intracellular protein activity. Nucleic Acids Res 34(12): 3577–84.
31. Fan X, Shi H, Adelman K, Lis JT (2004) Probing TBP interactions in
transcription initiation and reinitiation with RNA aptamers that act in distinct
modes. Proc Natl Acad Sci 101(18): 6934–9.
32. Fan X, Shi H, Lis JT (2005) Distinct transcriptional responses of RNA
polymerases I, II and III to aptamers that bind TBP. Nucleic Acids Res 33(3):
838–45.
33. Hong D, Said R, Falchook G, Naing A, Moulder S, et al. (2013) Phase I study of
BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory
metastatic or locally advanced solid tumors. Clinic Cancer Res 19(17): 4824–31.
34. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, et al. (2010)
Tanespimycin with bortezomib: activity in relapsed/refractory patients with
multiple myeloma. British Journal of Haematology 150(4): 428–37.
35. Wahner Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram
PP, et al. (2012) A phase II study of gemcitabine in combination with
tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Genecologic Oncology 124(2): 210–215.
36. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, et al. (2011) Multicenter
phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride
(IPI-504), in patients with castration-resistant prostate cancer. Urology 78(3):
626–30.

9

May 2014 | Volume 9 | Issue 5 | e96330

